Scientific publications and books linked to TransBioLine
2024
- E. Atallah, ‘Biomarkers of drug-induced liver injury’.
- Y. Z. Gu et al., ‘Magnitude of Urine Albumin and KIM-1 Changes Can be Used to Differentiate Glomerular Injury From Tubular Injury in Rats’, Toxicol Pathol.
- A.Kerkmann et al., ‘Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study’, Oncologist.
2023
- E. Atallah et al., ‘Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study’, JHEP Reports.
- E. Atallah et al., ‘Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated’, J Hepatol.
- E. S. Björnsson et al., ‘A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry’, Liver International.
- Z. Gai et al., ‘Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury’, Int J Mol Sci.
- J. I. Grove et al., ‘Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study’, Diagnostic and Prognostic Research.
- K. Vlasakova et al., ‘Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury’, Front Neurosci.
- S. Weber and A. L. Gerbes, ‘Relapse and Need for Extended Immunosuppression: Novel Features of Drug-Induced Autoimmune Hepatitis’, Digestion.
- S. Weber and A. L. Gerbes, ‘Update on herbal and dietary supplement-induced liver injury: current gaps and future directions’, Hepatobiliary Surg Nutr.
2022
- A. Diendorfer, et al. ‘miND (miRNA NGS Discovery pipeline): a small RNA-seq analysis pipeline and report generator for microRNA biomarker discovery studies’, F1000Research.
- A. L. Gerbes, ‘Drug-Induced Liver Injury (DILI): A Major Challenge’, Drug Res.
- C. Gutmann et al., ‘Association of cardiometabolic microRNAs with COVID-19 severity and mortality’, Cardiovasc Res.
- P. Huehnchen et al., ‘Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy’, JCI Insight.
- K. Khamina et al., ‘A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) for Genome-Scale Analysis and Absolute Quantitation of Circulating MicroRNA Biomarkers’, Int J Mol Sci.
- P. Szatmary et al., ‘Acute Pancreatitis: Diagnosis and Treatment’, Drugs.
- K. Vlasakova et al., ‘Plasma biomarkers TAP, CPA1, and CPA2 for the detection of pancreatic injury in rat: the development of a novel multiplex IA-LC-MS/MS assay and biomarker performance evaluation.’, Arch Toxicol.
- S. Weber and A. L. Gerbes, ‘Challenges and Future of Drug-Induced Liver Injury Research—Laboratory Tests’, Int J Mol Sci.
2021
- E. Atallah et al., ‘Biomarkers of idiosyncratic drug-induced liver injury (DILI) – a systematic review’, Expert Opin Drug Metab Toxicol.
- E. Atallah, et al., ‘Zanubrutinib-induced liver injury: a case report and literature review’, BMC Gastroenterol.
- K. A. Fader et al., ‘A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic’, J Pharmacol Exp Ther.
- H. P. Llewellyn et al., ‘Evaluating the Sensitivity and Specificity of Promising Circulating Biomarkers to Diagnose Liver Injury in Humans’, Toxicol Sci.
- Y. Ouyang et al., ‘Protective effects of necrostatin‐1 in acute pancreatitis: Partial involvement of receptor interacting protein kinase 1’, Cells.
- J. Sanabria-Cabrera et al., ‘Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry’, Liver Int.
- A. L. Schofield et al., ‘Systems analysis of miRNA biomarkers to inform drug safety’, Archives of Toxicology.
- L. Y. Takeshita et al., ‘Genomics and transcriptomics landscapes associated to changes in insulin sensitivity in response to endurance exercise training’, Scientific Reports.
- S. Weber, et al., ‘Monocyte-Derived Hepatocyte-Like Cell Test: A Novel Tool for in vitro Identification of Drug-Induced Liver Injury in Patients with Herbal or Dietary Supplements’, Digestion.
- S. Weber, et al., ‘Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury’, Digestive Diseases.
2020
- S. R. Atkinson et al., ‘In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers’, Am J Gastroenterol.
- M. A. Sheilabi, et al., ‘The Sodium Channel B4-Subunits are Dysregulated in Temporal Lobe Epilepsy Drug-Resistant Patients’, International Journal of Molecular Sciences.
- S. Weber and A. L. Gerbes, ‘Acute liver injury in a patient with adult-onset Still’s disease-the challenge of differential diagnosis’, Oxf Med Case Reports.
- C. for I. O. of M. S. (CIOMS), ‘Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting, A Consensus by a CIOMS Working Group’.
2019
- A.Benesic, et al., ‘Acute Liver Failure During Pirfenidone Treatment Triggered by Co-Medication With Esomeprazole’, Hepatology.
- A.Benesic, et al., ‘Drug-Drug Combinations Can Enhance Toxicity as Shown by Monocyte-Derived Hepatocyte-like Cells From Patients With Idiosyncratic Drug-Induced Liver Injury’, Toxicological Sciences.
- F. Gerhardt et al., ‘Iberogast-Induced Acute Liver Failure – Reexposure and in Vitro Assay Support Causality’, American Journal of Gastroenterology.
- S. Weber, et al., ‘Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis’, Liver International.